Skip to main content

Advertisement

Table 4 Impact of PAH-specific therapy and anticoagulation on health-related quality of life scores in SSc-PAH determined through mixed effects linear regression modeling

From: Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension

Variables Coefficient (95% CI) P value
Determinants of SF-36 physical component score
 Female gender 0.4 (−3.9, 4.7) 0.85
 Age at PAH diagnosis, years 0.1 (−0.1, 0.2) 0.29
 Diffuse disease subtype −0.3 (−3.8, 3.2) 0.87
 Combination therapy 1.7 (−1.5, 5.0) 0.29
 Anticoagulation therapy −3.7 (−7.1, −0.3) 0.03
 GIT involvementa 4.7 (0.9, 8.6) 0.01
 Digital ulcersa −3.7 (−7.2, −0.1) 0.04
Determinants of SF-36 mental component score
 Female gender −3.5 (−8.6, 1.6) 0.18
 Age at PAH diagnosis, years −0.1 (−0.2, 0.1) 0.67
 Diffuse disease subtype −1.1 (−5.2, 3.0) 0.59
 Combination therapy 5.2 (1.3, 9.1) 0.01
 Anticoagulation therapy −2.5 (−6.6, 1.6) 0.22
 GIT involvementa −1.6 (−6.2, 2.9) 0.48
 Digital ulcersa 2.8 (−1.5, 7.1) 0.19
Determinants of SHAQ score
 Female gender 0.3 (−0.5, 0.9) 0.46
 Age at PAH diagnosis, years −0.1 (−0.1, −0.1) 0.02
 Diffuse disease subtype −0.5 (−1.1, 0.2) 0.13
 Combination therapy −0.3 (−0.8, 0.3) 0.38
 Anticoagulation therapy 0.3 (−0.3, 0.9) 0.28
 GIT involvementa 0.7 (0.1, 1.3) 0.03
 Digital ulcersa −0.1 (−0.7, 0.5) 0.79
  1. Abbreviations: SSc systemic sclerosis, PAH pulmonary arterial hypertension, GIT gastrointestinal involvement, SHAQ scleroderma health assessment questionnaire
  2. aDisease manifestations present if present at PAH diagnosis or at any follow-up visit following PAH diagnosis